PARK Jae Hyung | 박재형

Professor of Chemical Engineering

031-290-7288
jhpark1@skku.edu
제1종합연구동 81717호

Research Areas

Nanomedicine

Research Interests

THERAGNOSTIC NANOMEDICINE FOR INTRACTABLE DISEASES
In recent years , advances in nanotechnology have made it possible to develop nanomedicine that allows treatment, diagnosis, monitoring, and control of biological systems. Nanomedicine, a n offshoot of nanotechnology, refers to highly specific, molecular-scale medical intervention for treating diseases or repairing damaged tissues. In our research group, much effort has been contributed to developing a novel type of polymeric nanomedicine for therapy and diagnosis of obstinate diseases such as cancer, rheumatoid arthritis, diabetes, and atherosclerosis. Also, we are trying to prepare biocompatible polymers that can be used as the constituent of the biomedical devices. To obtain the synergistic effects, our group is currently collaborating with many world-famous research groups regarding biomaterials, drug delivery system, and molecular imaging.

Selected Publications

1. Thambi T, Deepagan VG, Yoon HY, Han HS, Kim SH, Son S, Jo DG, Ahn CH, Suh YD, Kim K, Kwon IC, Lee DS, Park JH. Hypoxia-responsive polymeric nanoparticles for tumor-targeted drug delivery. Biomaterials 2014;35:1735-1743.

2. Park JH, Cho HJ, Yoon HY, Yoon IS, Ko SH, Shim JS, Cho JH, Park JH, Kim K, Kwon IC, Kim DD. Hyaluronic acid derivative-coated nanohybrid liposomes for cancer imaging and drug delivery. J Control Release 2014;174:98-108.

3. Ryu JH, Na JH, Ko HK, You DG, Park S, Jun E, Yeom HJ, Seo DH, Park JH, Jeong SY, Kim IS, Kim BS, Kwon IC, Choi K, Kim K. Non-invasive optical imaging of cathepsin B with activatablefluorogenicnanoprobes in various metastatic models. Biomaterials 2014;35:2302-2311.

4. Min SH, Son S, Lee TW, Koo H, Yoon HY, Na JH, Choi Y, Park JH, Lee J, Han MH, Park RW, Kim IS, Jeong SY, Rhee K, Kim SH, Kwon IC, Kim K. Liver-specific and echogenic hyaluronic acid nanoparticles facilitating liver cancer discrimination. Adv Funct Mater 2013;23:5518-5529 (Selected as the Cover Feature).

5. Yoon HY, Kim HR, Saravanakumr G, Heo R, Chae SY, Um W, Kim K, Kwon IC, Lee JY, Lee DS, Park JC, Park JH. Bioreducible hyaluronic acid conjugates as siRNA carrier for tumor targeting. J Control Release 2013;172:653-661.

6. Koo H, Min KH, Lee SC, Park JH, Park K, Jeong SY, Choi K, Kwon IC, Kim K. Enhanced drug-loading and therapeutic efficacy of hydrotropic oligomer-conjugated glycol chitosan nanoparticles for tumor-targeted paclitaxel delivery. J Control Release 2013;172:823-831.

7. Kim SH, Kim JH, You DG, Saravanakumar G, Yoon HY, Choi KY, Thambi T, Deepagan VG, Jo DG, Park JH. Self-assembled dextran sulphate nanoparticles for targeting rheumatoid arthritis. ChemCommun 2013;49:10335-10434 (Selected as the Cover Feature).

8. Kim TH, Swierczewska M, Oh Y, Kim A, Jo DG, Park JH, Byun Y, Sadegh-Nasseri S, Pomper MG, Lee KC, Lee S. Mix to validate: A facile, reversible PEGylation for fast screening of potential therapeutic proteins in vivo. AngewChemInt Edit 2013;52:6880-6884 (Selected as the Cover Feature).

9. Yoon HY, Koo H, Choi KY, Kwon IC, Choi K, Park JH, Kim K. Photo-crosslinked hyaluronic aicd nanoparticles with improved stability for in vivo tumor-targeted drug delivery. Biomaterials 2013;34:5273-5280.

10. Han HS, Lee J, Kim HR, Chae SY, Kim M, Saravanakumar G, Yoon HY, You DG, Ko H, Kim K, Kwon IC, Park JC, Park JH, Robust PEGylated hyaluronic acid nanoparticles as the carrier of doxorubicin: Mineralization and its effect on tumortargetabilityin vivo. J Control Release 2013;168;105-114.

Professional Experience

– 한국과학기술연구원 박사후연구원 (2002 – 2004)
– Purdue University 박사후 연구원 (2004- 2005)
– 경희대학교 화학공학부 조교수/부교수 (2005-2011)
– 삼성융합의과학원 겸직교수 (2012-현재)

메뉴